Navigation Links
Breakthrough for IVF?
Date:5/17/2013

Amsterdam, May 17, 2013 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a recent study in Reproductive BioMedicine Online on 5-day old human blastocysts showing that those with an abnormal chromosomal composition can be identified by the rate at which they have developed to blastocysts, thereby classifying the risk of genetic abnormality without a biopsy. In a new study the same group has undertaken a retrospective study, using their predictive model to assess the likelihood of any embryo transferred resulting in a successful pregnancy, with very encouraging outcomes.

One of the greatest challenges in assisted reproduction is to find the one embryo, which can develop successfully. Now, combining time lapse imaging of IVF embryos cultured for 5 days to the blastocyst stage with trophoblast biopsy, it has proved possible to correlate the rate of blastocyst formation with chromosomal abnormalities. Such an approach should allow early and widely accessible non-invasive identification of the best embryo to place in the uterus.

"Recently the world of IVF has become very excited by the use of time-lapse imaging (TLI) of early human embryo development to follow the change of embryo morphology over time", explains Martin Johnson, Editor of Reproductive BioMedicine Online. "The data can then be compared with the outcome after the embryos are transferred. The hope is that this morphokinetic analysis will enable reproductive specialists to predict more successfully those embryos most likely to generate pregnancies. The advantage of using morphokinetic analysis to predict outcome is its minimal invasiveness."

The majority of embryos that fail to initiate a pregnancy do so because they have abnormal chromosomes. Unfortunately these embryos cannot be recognized by embryologists using conventional microscopy. Only biopsy of one or a few cells of the early embryo followed by preimplantation genetic screening (PGS) can establish whether the number of chromosomes is normal or not.

In their research Alison Campbell and colleagues of CARE Fertility, Nottingham, went one step further, describing the use of morphokinetic analysis to identify those embryos that have an abnormal chromosomal constitution. In that study, they cultured embryos under time lapse imaging to day 5, by which time they formed blastocysts. These were then biopsied by removing a few of the cells from the outer layer of the embryo, which will normally contribute only to the placenta. The biopsy was then analyzed for its chromosomal constitution. The authors then related the chromosomal make up of each embryo to its morphokinetic history. They found that a proportion of embryos with chromosomal abnormalities were delayed in initiating blastocyst formation and also reached the full blastocyst stage later than did normal embryos. The authors conclude that using this approach they could avoid exposing at least a subset of the embryos to invasive biopsy procedures.

"This non-invasive model for the classification of chromosomal abnormality may be used to avoid selecting embryos with high risk of aneuploidy while selecting those with reduced risk," said lead author Alison Campbell.

The same group has now applied this risk classification model retrospectively to examine the pregnancy outcomes in a series of unselected IVF patients without the use of PGS. A significant improvement in both implantation and live birth rates was observed when low risk embryos were transferred.

Scientist Markus Montag of the Department of Gynecological Endocrinology and Fertility Disorders, University Clinics of Heidelberg, said: "The idea of using time-lapse imaging and morphokinetic analysis is intriguing, because having available a completely non-invasive procedure to predict which embryo is euploid or aneuploid would allow the application of this technique for virtually every assisted reproduction cycle. The potential benefit of such an approach is obvious in view of published data on the incidence of aneuploidy even in oocytes from younger women."


'/>"/>

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Related biology technology :

1. Microfabrication breakthrough could set piezoelectric material applications in motion
2. Transparent material breakthrough
3. U of Toronto experiment named top breakthrough of 2011 by Physics World
4. Almost perfect: A breakthrough in superlens development
5. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
6. Research breakthrough takes supercomputing out of the lab
7. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
8. Breakthrough by U of T-led research team leads to record efficiency for next-generation solar cells
9. Breakthrough in nanotechnology
10. Doctors Without Borders and DNDi: Millions of Patients Still Waiting for Medical “Breakthroughs” Against Neglected Diseases
11. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
Breaking Biology News(10 mins):